Premium
A Polymer–(Tandem Drugs) Conjugate for Enhanced Cancer Treatment
Author(s) -
Zhou Dongfang,
Xiao Haihua,
Meng Fanbo,
Li Xiaoyuan,
Li Yuxin,
Jing Xiabin,
Huang Yubin
Publication year - 2013
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.201200385
Subject(s) - conjugate , cisplatin , serine , protein phosphatase 2 , cancer cell , pharmacology , tandem , chemistry , cancer research , chemotherapy , cancer , combinatorial chemistry , phosphatase , materials science , biochemistry , medicine , phosphorylation , surgery , mathematical analysis , mathematics , composite material
A novel strategy for combination chemotherapy (platinum and demethylcantharidin) via a polymer–(tandem drugs) conjugate for enhanced cancer treatment is demonstrated. Cisplatin can be released inside cell by reduction to attack DNA, while DMC will be hydrolyzed subsequently to block DNA‐damage‐induced defense mechanisms by serine/threonine phosphatase PP2A inhibition. Synergistic effect of the polymer–(tandem drugs) conjugate causes complete suppression of H22 liver tumor xenografts without recurrence.